Citigroup
TXMD icon

Citigroup’s TherapeuticsMD TXMD Stock Holding History

Citigroup’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,706
Closed -$103K – 7403
2020
Q4 		$103K Buy
1,706
+250
+17% +$17.1K ﹤0.01% 5512
2020
Q3 		$115K Sell
1,456
-322
-18% -$25.7K ﹤0.01% 5013
2020
Q2 		$111K Buy
1,778
+124
+7% +$7.22K ﹤0.01% 5498
2020
Q1 		$88K Sell
1,654
-594
-26% -$58.9K ﹤0.01% 5454
2019
Q4 		$272K Buy
2,248
+674
+43% +$96.9K ﹤0.01% 4924
2019
Q3 		$286K Buy
1,574
+662
+73% +$93.3K ﹤0.01% 4854
2019
Q2 		$119K Sell
912
-128
-12% -$22.9K ﹤0.01% 5715
2019
Q1 		$253K Buy
1,040
+362
+53% +$95.8K ﹤0.01% 4868
2018
Q4 		$129K Sell
678
-78
-10% -$19K ﹤0.01% 5436
2018
Q3 		$248K Sell
756
-260
-26% -$79.7K ﹤0.01% 5024
2018
Q2 		$317K Buy
1,016
+584
+135% +$178K ﹤0.01% 4575
2018
Q1 		$105K Sell
432
-34
-7% -$9.54K ﹤0.01% 5574
2017
Q4 		$141K Buy
466
+464
+23,200% +$129K ﹤0.01% 5337
2017
Q3 		$1K Buy
+2
New +$578 ﹤0.01% 7160

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Citigroup's TXMD Position: Q2 2026 in Review

Citigroup opened a new position in TherapeuticsMD (TXMD) in Q2 2026: 64 shares worth $141. The stake represents ﹤0.01% of the portfolio and ranks #5509 among its holdings. This is a return to the name: Citigroup previously reported a position in TXMD as recently as Q4 2025.

Citigroup first reported a position in TXMD in Q2 2013 and has held it in 41 quarters since. The position peaked at $1.56M in Q1 2021. 44 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • Citigroup held 64 shares of TherapeuticsMD worth $141 as of Q2 2026.
  • TherapeuticsMD was a new Citigroup position in Q2 2026.
  • TherapeuticsMD made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5509 holding.
  • Citigroup first reported a position in TherapeuticsMD in Q2 2013 and has held it in 41 quarters since.
  • Citigroup's TherapeuticsMD position peaked at $1.56M in Q1 2021.
  • 44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.